Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pengpeng Liang

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Cardiovascular Pharmacology and Therapeutics|April 24, 2024
The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of AtherosclerosisXin Zhang, Suwen Chen, Guoliang Yin, et al.
Frontiers in Pharmacology|December 12, 2022
Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation <i>in vitro</i> and <i>in vivo</i>Guoliang Yin, Hongyi Liang, Wenxiu Sun, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|September 23, 2021
The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A ReviewFengcui Sun, Xiufen Yang, Chaoqun Ma, et al.
European Journal of Pharmacology|June 1, 2023
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathwaySuwen Chen, Shangwen Sun, Yanan Feng, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Cardiovascular Pharmacology and Therapeutics|April 24, 2024
The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of AtherosclerosisXin Zhang, Suwen Chen, Guoliang Yin, et al.
Frontiers in Pharmacology|December 12, 2022
Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation <i>in vitro</i> and <i>in vivo</i>Guoliang Yin, Hongyi Liang, Wenxiu Sun, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|September 23, 2021
The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A ReviewFengcui Sun, Xiufen Yang, Chaoqun Ma, et al.
European Journal of Pharmacology|June 1, 2023
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathwaySuwen Chen, Shangwen Sun, Yanan Feng, et al.
Pageof 3